Strand Life Sciences, India, has announced about their collaboration with the U.S.-based Global Diagnostics Network (GDN).
The initiative aims for standardized delivery and development of high quality companion diagnostics for pharmaceutical companies, and the creation of an emerging pathogen preparedness network to expedite infectious disease research and response.
The GDN, which is a network of Quest Diagnostics, launched in October 2018, is a working group of major diagnostic laboratories collaborating to generate enhanced diagnostics insights. It consist of companies including Al Borg Medical Laboratories, Dasa, GC Labs, Healius, KingMed Diagnostics, SYNLAB and LSI Medience.
Strand Life Sciences is a pioneer in precision medicine solutions aimed to make better healthcare decision- making with its access to a wide geographical network of diagnostic laboratories in India.
In India, Strand is focused on oncology, mother and child, and technology enabled wellness segments.
“We are very pleased to join the GDN and learn from the rich experience of our fellow members as well as contribute through our special capabilities in genetics, bioinformatics and oncology” said Harish Natarajan, Chief Operating Officer and President, Clinical Diagnostics at Strand Life Sciences in a press release.
“We welcome Strand Life Sciences as a new GDN member, and are eager to continue acceleration of the network’s programmes that will reach patients in every part of the world,” said Mark Machulcz, General Manager, Global Markets at Quest Diagnostics. “The GDN continues to make great strides in increasing access to diagnostic technology and innovation, and in building the largest global launch platform for rapid deployment of companion diagnostics.”